A
Alcista
Alcista · 25%IART
$15.78
Precio del escenario
$13.210
-0.313 (-2.37%)Al cierre
Loading chart…
- Máximo
- 13.830
- Apertura
- 13.650
- Precio medio ponderado por volumen
- 13.38
- Volumen
- 831.02K
- Capitalización
- 2.27B
- Mínimo
- 13.100
- Importe
- 11.12M
- EV/EBITDA, TTM
- 9.04
Integra LifeSciences Holdings Corporation is a global medical technology company. It manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others.
Análisis de IA of Integra Lifesciences Holdings Corp (IART)
MantenerIntegra Lifesciences Holdings Corp (IART) is currently not a strong buy due to its recent performance and analyst downgrades. The current price is $13.21, which is below the adjusted analyst price target of $15. Additionally, the RSI is at 36.99, indicating that the stock is nearing oversold territory but has not yet shown a strong reversal signal. The company has faced challenges, including a significant net income loss of $484 million in Q2 2025, which raises concerns about its profitability moving forward. However, the gross margin remains relatively healthy at 54.90% in Q2 2026, suggesting some operational efficiency. The main risk is the company's high debt-to-equity ratio of 179.45%, which could limit financial flexibility and growth opportunities.
Recomendaciones de analistas (15)
-6.66% Potencial de caída
Comprar
9 Comprar
6 Mantener
0 Vender
Actual: 13.21
Mínimo
10.00
Promedio
12.33
Máximo
14.00
BMO Capital
Market Perform
$15
2026-10-05
BMO Capital
2026-10-05
Precio objetivo
$15
Market Perform
Citi
Neutral
$15
2026-10-05
Citi
2026-10-05
Precio objetivo
$15
Neutral
Wells Fargo
Equal Weight
$15
2026-10-03
Wells Fargo
2026-10-03
Precio objetivo
$15
Equal Weight
UBS
Neutral
$19
2026-07-28
UBS
2026-07-28
Precio objetivo
$19
Neutral
Truist
Mantener
$19
2026-07-16
Truist
2026-07-16
Precio objetivo
$19
Mantener
Métricas de valoración
El PER previsto actual de Integra Lifesciences Holdings Corp (IART) es 6.00, frente a su media de 5 años de 11.66.
Escenarios de precio de Alphio AI para IART
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con IART en cartera
Cronología de eventos
Noticias
1.010-16NewsfilterIntegra LifeSciences to Showcase ENT Innovations at AAO-HNSF Annual Meeting
- 8.510-09Newsfilter
Integra LifeSciences Prices $450 Million Senior Secured Notes Offering
4.510-05PRnewswireWall Street Market Dynamics Analysis
4.510-05NewsfilterWall Street Market Dynamics Analysis
- 4.510-03Newsfilter
Tech Stocks Propel Nasdaq Gains Amid Mixed Market Performance
Preguntas frecuentes sobre IART, respondidas por Alphio AI
Integra LifeSciences Holdings Corporation is a global medical technology company. It manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Integra Lifesciences Holdings Corp (IART) is currently not a strong buy due to its recent performance and analyst downgrades. The current price is $13.21, which is below the adjusted analyst price target of $15. Additionally, the RSI is at 36.99, indicating that the stock is nearing oversold territory but has not yet shown a strong reversal signal. The company has faced challenges, including a significant net income loss of $484 million in Q2 2025, which raises concerns about its profitability moving forward. However, the gross margin remains relatively healthy at 54.90% in Q2 2026, suggesting some operational efficiency. The main risk is the company's high debt-to-equity ratio of 179.45%, which could limit financial flexibility and growth opportunities.
15 analysts cover IART: 9 rate it Buy, 6 Hold and 0 Sell. The average price target is 12.33.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.